Clinical Trials
3 trialsNCT06351631 2026-04-02
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04262141 2026-01-07
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
University of Miami
Phase 2 Active not recruiting
NCT05223920 2025-09-22
MK-3543-005
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed